Compare C3.ai Inc (AI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
C3.ai Inc vs Merck & Co., Inc. — how do they compare? C3.ai Inc trades at $12.46 (market cap $2.00B), while Merck & Co., Inc. trades at $145.27 (market cap $358.41B). The key difference: Merck & Co., Inc. is far larger — about 179.2× C3.ai Inc's market cap, and Merck & Co., Inc. pays a 2.34% dividend while C3.ai Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold C3.ai Inc for 137 Days and Merck & Co., Inc. for 96 Days on average.
| AI | MRK | |
|---|---|---|
Market Cap | $2.00B | $358.41B |
Volume | 5,843,049 | 8,378,881 |
Sector | Technology | Health |
52-Week High | $18.36 | $156.43 |
52-Week Low | $7.76 | $82.49 |
Typical Hold Time | 137 Days | 96 Days |
Enterprise Value | $1.36B | $405.17B |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
C3.ai (AI) trades at $12.03, up 2.04% today, with a bullish technical signal supported by moving averages. The company shows revenue growth from $253M in 2022 to $389M in 2025, but remains unprofitable with a -192.1% net income margin. Recent earnings beat expectations in Q1 and Q2 2026, though Q4 2025 missed. Analyst sentiment is mixed with 21% buy ratings and a $11.25 consensus target.
The outlook remains challenging due to persistent losses and cash burn, though revenue growth and AI sector momentum offer potential. Key risks include high valuation multiples, negative cash flow, and insider selling. Investors should weigh the company's growth trajectory against its path to profitability.
Merck (MRK) trades at $147.24, down 1.79% today, amid a bullish technical setup with key support at $143 and resistance at $153. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.09. Revenue reached $65.01B in 2025, and net income margin improved to 28.07%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
The outlook for MRK is positive, supported by analyst consensus favoring Buy ratings (68.42%) and a price target of $157.94, implying ~7% upside. Risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the pharma sector. Investors should monitor execution of the Terns acquisition and upcoming Q3 earnings for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
